Computable structured aptamer for targeted treatment of ovarian cancer

Ruan, Luoshan; Han, Li-Ting; Li, Xin; Chen, Xin; Sun, Gege; Wang, Xinyu; Luo, Yan; Gu, Chuanqi; Shi, Xiaolong

doi:10.3389/fgene.2023.1170260

Cited by 4 publications

(1 citation statement)

References 45 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…HA-6AS-DOX and ST-6AS-DOX demonstrated rapid cytotoxicity specifically against OC cells while exhibiting low levels of cytotoxicity towards normal ovarian epithelial cells. Additionally, the study revealed contrasting internalization patterns between HA-6AS and ST-6AS; HA-6AS displayed a more active targeting mechanism, whereas ST-6AS exhibited a predominantly passive targeting mechanism [118].…”

Section: Nucleolinmentioning

confidence: 90%

Aptamers as Potential Therapeutic Tools for Ovarian Cancer: Advancements and Challenges

Szymanowski,

Szymanowska,

Bielawska

et al. 2023

Cancers

View full text Add to dashboard Cite

Ovarian cancer (OC) is the most common lethal gynecologic cause of death in women worldwide, with a high mortality rate and increasing incidence. Despite advancements in the treatment, most OC patients still die from their disease due to late-stage diagnosis, the lack of effective diagnostic methods, and relapses. Aptamers, synthetic, short single-stranded oligonucleotides, have emerged as promising anticancer therapeutics. Their ability to selectively bind to target molecules, including cancer-related proteins and receptors, has revolutionized drug discovery and biomarker identification. Aptamers offer unique insights into the molecular pathways involved in cancer development and progression. Moreover, they show immense potential as drug delivery systems, enabling targeted delivery of therapeutic agents to cancer cells while minimizing off-target effects and reducing systemic toxicity. In the context of OC, the integration of aptamers with non-coding RNAs (ncRNAs) presents an opportunity for precise and efficient gene targeting. Additionally, the conjugation of aptamers with nanoparticles allows for accurate and targeted delivery of ncRNAs to specific cells, tissues, or organs. In this review, we will summarize the potential use and challenges associated with the use of aptamers alone or aptamer–ncRNA conjugates, nanoparticles, and multivalent aptamer-based therapeutics for the treatment of OC.

show abstract

Section: Nucleolinmentioning

confidence: 90%

Aptamers as Potential Therapeutic Tools for Ovarian Cancer: Advancements and Challenges

Szymanowski,

Szymanowska,

Bielawska

et al. 2023

Cancers

View full text Add to dashboard Cite

show abstract

Engineering Nano‐Pills to Inhibit Ovarian Cancer Proliferation and Migration through a Combination of Chemical/Nucleic Acid Therapy

Jia,

Liu,

Zhang

et al. 2024

Small

View full text Add to dashboard Cite

Ovarian cancer (OC) is the most fatal of all gynecological malignancies, presenting a significant threat to women's health. Its treatment is complicated by severe dose‐dependent chemotherapy toxicity, drug resistance, and tumor migration. Herein, an intelligent combination strategy of chemotherapy and nucleic acid therapy, named ApMEmiR&D is developed. This integrated system consists of three parts: the nano‐pill, the protective membrane, and the navigation element. Nano‐pills are nanospheres assembled from miRNA and doxorubicin (DOX) with the help of ferrous ions (Fe2+). The protective membrane is derived from tumor‐associated macrophages (TAMs membrane) originating from the primary tumor microenvironment (TME). The navigation element is the cholesterol‐conjugated AS1411 aptamer. The resulting ApMEmiR&D nanoparticles exhibit uniform size, a well‐defined nanosphere structure, robust serum stability, and ultra‐high drug loading efficiency and capacity. The system can efficiently accumulate in the tumor, allowing for the synergistic inhibition of tumor growth and metastasis without apparent systemic toxicity. The results demonstrate the homing effect of tumor microenvironment‐derived macrophage cell membrane and the targeting effect of aptamer, leading to precise drug targeting and immune compatibility, thereby enhancing therapeutic efficacy. The success of this strategy paves the way for metastasis inhibition and targeted cancer therapy.

show abstract

Current developments of SELEX technologies and prospects in the aptamer selection with clinical applications

Chinchilla-Cárdenas,

Cruz-Méndez,

Petano-Duque

et al. 2024

Journal of Genetic Engineering and Biotechnology

View full text Add to dashboard Cite

Computable structured aptamer for targeted treatment of ovarian cancer

Cited by 4 publications

References 45 publications

Aptamers as Potential Therapeutic Tools for Ovarian Cancer: Advancements and Challenges

Aptamers as Potential Therapeutic Tools for Ovarian Cancer: Advancements and Challenges

Engineering Nano‐Pills to Inhibit Ovarian Cancer Proliferation and Migration through a Combination of Chemical/Nucleic Acid Therapy

Current developments of SELEX technologies and prospects in the aptamer selection with clinical applications

Contact Info

Product

Resources

About